Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jun 25:8:698534.
doi: 10.3389/fmed.2021.698534. eCollection 2021.

Regulatory Standards in Orphan Medicinal Product Designation in the EU

Stelios Tsigkos  1 , Segundo Mariz  1 , Maria Elzbieta Sheean  1 , Kristina Larsson  1 , Armando Magrelli  2   3 , Violeta Stoyanova-Beninska  3   4
Affiliations
Review

Regulatory Standards in Orphan Medicinal Product Designation in the EU

Stelios Tsigkos et al. Front Med (Lausanne). .

Abstract

Twenty years of orphan regulation in Europe have now elapsed, with almost 2,400 orphan designated medicinal products and more than 190 orphan products authorised in the EU. Alongside the evolution in understanding of rare diseases, considerable regulatory knowledge has also been accumulated regarding the level of evidence that would support inclusion of products into the framework. This article reviews publications and regulatory documents pertaining to orphan medicinal product designation in the EU and discusses the general expectations in submitted applications as reflected in the current regulatory practise. Important elements to recommend granting a European orphan designation are the key considerations of orphan condition, medical plausibility, seriousness, and prevalence, while significant benefit is also assessed when there are authorised medicinal products for the sought indication. This review attempts to clarify the specific concepts currently used in that regard and discusses how the available data can be used to justify the criteria for designation. Moving away from theoretical expectations or assumptions, it stresses that the applications have to be complemented with nosological and epidemiological justifications pertaining to the proposed condition, as well as relevant data in specific non-clinical in vivo models or in affected patients to support inclusion into the orphan scheme.

Keywords: COMP; market exclusivity; orphan designation; orphan medicinal product; orphan regulation; significant benefit.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Regulation (EC) No.141/2000 of the European Parliament and of the council, of 16 December 1999 on orphan medicinal products . Official Journal L 018, 22/01/2000.
    1. EMA . Orphan Medicines Figures 2000-2020. Available online at: https://www.ema.europa.eu/en/documents/other/orphan-medicines-figures-20... (accessed June 16, 2021).
    1. Guideline on the format and content of applications for designation as orphan medicinal products and on the transfer of designations from one sponsor to another ENTR/6283/00 Rev.5
    1. O'Connor DJ, Sheean ME, Hofer MP, Tsigkos S, Mariz S, Fregonese L, et al. . Defining orphan conditions in the context of the European orphan regulation: challenges and evolution. Nat Rev Drug Discov. (2019) 18:479–80. 10.1038/nrd2018128 - DOI - PubMed
    1. Commission notice on the application of Articles 3 5 and 7 of Regulation (EC) No 141/2000 on orphan medicinal products (2016/C 424/03) .